Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
Allarity Therapeutics Inc ALLR shares are trading higher on a strong session volume of 67 million, as per the data from Benzinga Pro. The company announced…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 HUTCHMED Limited today announces that new and updated data from several studies of compounds discovered by HUTCHMED will.
HUTCHMED Highlights Data to be Presented at AACR Congress 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.